Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#OBJECT> ?p ?o ?g. }
- OBJECT label "that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety" provenance.
- OBJECT label "that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety" provenance.
- OBJECT label "that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety" provenance.
- OBJECT label "that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety" provenance.
- OBJECT label "that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety" provenance.
- OBJECT label "that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "with lenalidomide and dexamethasone alone ( Rd )" provenance.
- OBJECT label "that The dexamethasone reduced the death rate in The coronavirus disease 2019 ( COVID)-19 ) patients" provenance.
- OBJECT label "that The dexamethasone reduced the death rate in The coronavirus disease 2019 ( COVID)-19 ) patients" provenance.
- OBJECT label "that The dexamethasone reduced the death rate in The coronavirus disease 2019 ( COVID)-19 ) patients" provenance.
- OBJECT label "that The dexamethasone reduced the death rate in The coronavirus disease 2019 ( COVID)-19 ) patients" provenance.
- OBJECT label "that The dexamethasone reduced the death rate in The coronavirus disease 2019 ( COVID)-19 ) patients" provenance.
- OBJECT label "by up, third among COVID-19 patients on mechanical ventilation and one-fifth among" provenance.
- OBJECT label "by up, third among COVID-19 patients on mechanical ventilation and one-fifth among" provenance.
- OBJECT label "by up, third among COVID-19 patients on mechanical ventilation and one-fifth among" provenance.
- OBJECT label "age specific months of mortality , abbreviated MOMa from 12 to 7 months" provenance.
- OBJECT label "age specific months of mortality , abbreviated MOMa from 12 to 7 months" provenance.
- OBJECT label "age specific months of mortality , abbreviated MOMa from 12 to 7 months" provenance.
- OBJECT label "age specific months of mortality , abbreviated MOMa from 12 to 7 months" provenance.
- OBJECT label "age specific months of mortality , abbreviated MOMa from 12 to 7 months" provenance.
- OBJECT label "age specific months of mortality , abbreviated MOMa from 12 to 7 months" provenance.
- OBJECT label "age specific months of mortality , abbreviated MOMa from 12 to 7 months" provenance.
- OBJECT label "age specific months of mortality , abbreviated MOMa from 12 to 7 months" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality in hospitalized patients, COVID-19 who required respiratory support" provenance.
- OBJECT label "mortality of severe COVID-19 patients only" provenance.
- OBJECT label "mortality of severe COVID-19 patients only" provenance.
- OBJECT label "mortality of severe COVID-19 patients only" provenance.
- OBJECT label "mortality of severe COVID-19 patients only" provenance.
- OBJECT label "mortality of severe COVID-19 patients only" provenance.
- OBJECT label "mortality of severe COVID-19 patients only" provenance.
- OBJECT label "mortality of severe COVID-19 patients only" provenance.
- OBJECT label "mortality of severe COVID-19 patients only" provenance.
- OBJECT label "the number of cells expressing iNOS" provenance.
- OBJECT label "the number of cells expressing iNOS" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "significant reduction in the release of TNFα , IL-6 , IL-1β and IL-8" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.
- OBJECT label "a significantly shorter , total duration of oxygen supplementation , ( 10 , 45 d , vs , 21 , 61 , d , , P - value=0 , 003 ) and length of stay in the hospital ( 19 76 d , vs 27 , 21 , d , , P - value=0 , 013 ) , However , , extracorporeal membrane , oxygenation and in - hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia ( early , dexamethasone , group ) or 24 hours" provenance.